Swiss Stakeholder Event:
Insights into CEPI’s New Strategic Priorities

CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats.

CEPI leverages its unique position within the global health and R&D ecosystems to address market failures, building on its track record of bringing together public-sector, private-sector, and academic partners to accelerate the development of vaccines against emerging viral threats.

CEPI supports the development of vaccines, platform technologies and manufacturing innovations to combat priority pathogens for which no licensed vaccines are currently available.

CEPI is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.

CEPI has backed the development of 30+ vaccine candidates for its priority pathogens, overseeing scientific breakthroughs, including the first-ever approved Chikungunya vaccine, and advancing the first-ever Nipah vaccine into Phase I and the first-ever Lassa fever vaccine into Phase II trials. A key player in the COVID-19 response, CEPI also has one of the world’s largest COVID-19 vaccine portfolios and co-led COVAX, which helped to distribute nearly 2 billion doses to 146 nations.